phrykt

TuHURA Biosciences, Inc./NV (HURA): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of HURA were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling TuHURA Biosciences

From the latest filings

Overall: more selling than buying. Famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns HURA

89 funds and institutions reported HURA shares worth $21M at the end of Q2 2026, about 14% of the company. The largest holder is Vanguard Capital Management LLC with 3.6%.

Funds and institutions (13F) 14%Everyone else 86%

10 largest owners, by share of the company

Vanguard Capital Management LLC3.6%
Northern Trust Corp2.5%
BlackRock, Inc.1.1%
Geode Capital Management, LLC0.8%
Millennium Management LLC0.7%
AQR Capital Management LLC0.7%
Vanguard Fiduciary Trust Co0.4%
Citadel Advisors LLC0.4%
State Street Corp0.3%
Jane Street Group, LLC0.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Vanguard Capital Management LLC2.27M3.57%$5.3M+9%
Northern Trust Corp1.62M2.55%$3.8M+444%
BlackRock, Inc.690,0881.09%$1.6M-72%
Geode Capital Management, LLC484,2190.76%$1.1M-51%
Millennium Management LLC454,5350.71%$1.1MNew
AQR Capital Management LLC424,6000.67%$994K-30%
Vanguard Fiduciary Trust Co251,1860.40%$588K-13%
Citadel Advisors LLC232,3190.37%$544KNew
State Street Corp188,4040.30%$441K-63%
Jane Street Group, LLC163,8910.26%$384KNew
Apollon Wealth Management, LLC156,5190.25%$366K-1%
Qube Research & Technologies Ltd145,5950.23%$341KNew
Morgan Stanley143,2570.23%$335K+501%
Goldman Sachs Group Inc131,7680.21%$308K+88%
Bank of New York Mellon Corp121,6620.19%$285K-42%
XTX Topco Ltd100,4240.16%$235K+772%
WealthShield Partners, LLC91,5300.14%$214KNo change
Aster Capital Management (DIFC) Ltd89,6900.14%$210KNew
Captrust Financial Advisors88,3730.14%$207KNew
Cetera Investment Advisers61,6200.10%$144K-56%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No HURA insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

HURA short interest

Moderate short interest. 9.7% of HURA shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 22%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.20M HURA shares were sold short, 9.7% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 491,335 shares, buying them all back would take about 12.6 trading days (days to cover).

Shares short, % of all shares

9.73%May 15Oct 3013.9%

Days to cover

12.6May 15Oct 3036.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.20M9.73%+4%491,33512.6
Oct 15, 20265.94M9.32%-3%221,06926.9
Sep 30, 20266.10M9.57%-3%214,84228.4
Sep 15, 20266.28M9.85%+0%192,76432.6
Aug 31, 20266.27M9.84%-1%224,41627.9
Aug 14, 20266.32M9.92%-3%301,57521.0
Jul 31, 20266.51M10.23%-2%204,29731.9
Jul 15, 20266.65M10.45%-5%429,28715.5
Jun 30, 20266.99M11.00%-10%1.02M6.9
Jun 15, 20267.76M12.21%-8%467,07516.6
May 29, 20268.44M13.28%+6%572,40914.8
May 15, 20267.98M12.56%-3%578,80813.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded HURA

Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 0 sales of HURA. The latest was a purchase by Laurel M. Lee on Jul 13, 2025, reported Aug 9, 2025.

Purchases 2Sales 0

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Jul 13, 2025Laurel M. Lee (R-FL)Purchase$50K–$100KSpouseAug 9, 2025Report
Nov 25, 2024Laurel M. Lee (R-FL)Purchase$1K–$15KSpouseJan 7, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

TuHURA Biosciences company events

TuHURA Biosciences filed 25 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Nov 6, 2026.

  1. Nov 6, 2026DebtTook on new debt. Filing
  2. Oct 16, 2026DebtTook on new debt. Filing
  3. Sep 24, 2026DebtTook on new debt. Filing
  4. Sep 17, 2026DebtTook on new debt. Filing
  5. Sep 17, 2026LeadershipAmended an earlier report. Of the Form 8-K filed on September 16, 2026 in order to provide the following additional information regarding the Inducement Plan (as defined in the Original 8-K): (i) the Company has not yet, as of the date of the adoption of the Inducement Plan, granted any equity awards under the Inducement… Filing
  6. Sep 16, 2026LeadershipThe Board of Directors of TuHURA Biosciences, Inc. adopted the TuHURA Biosciences, Inc. 2026 Inducement Equity Incentive Plan, pursuant to which the Company may from time to time grant equity awards to new employees as a material inducement to their entering into employment with the Company or one… Filing
  7. Sep 4, 2026DebtTook on new debt. Filing
  8. Aug 21, 2026DebtTook on new debt. Filing
  9. Aug 19, 2026SharesSold new shares outside a public offering. Filing
  10. Aug 14, 2026ResultsReleased financial results. Filing
  11. Aug 13, 2026DebtTook on new debt. Filing
  12. Jul 29, 2026DebtTook on new debt. Filing
  13. Jul 7, 2026DebtTook on new debt. Filing
  14. Jun 17, 2026VoteSet dates for shareholder nominations. Filing
  15. May 29, 2026DebtTook on new debt. Filing
  16. May 15, 2026ResultsReleased financial results. Filing
  17. Apr 30, 2026AnnouncementAmended an earlier report. Updated Pro Forma Financial Statements As previously disclosed, on June 30, 2025, the Company completed its previously announced acquisition contemplated by the Agreement and Plan of Merger, dated December 11, 2024, as amended by that certain First Amendment to Agreement and Plan of Merger, dated… Filing
  18. Apr 22, 2026AgreementTuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC, as lender, under which Parkview agreed to extend a $50 million revolving credit facility to the Company upon the terms and conditions set forth in the Loan Agreement. Filing
  19. Apr 8, 2026LeadershipThe Compensation Committee of the Board of Directors of TuHURA Biosciences, Inc. approved annual performance bonuses for 2025 for Dr. James Bianco, the Company’s President and Chief Executive Officer, and Dan Dearborn, the Company’s Chief Financial Officer, in the amount of $490,536 for Dr. Bianco… Filing
  20. Apr 1, 2026ResultsReleased financial results. Filing
  21. Jan 30, 2026ListingTuHURA Biosciences, Inc. received a letter from The Nasdaq Stock Market LLC indicating that the Company’s consolidated closing bid price has been below $1.00 per share for 35 consecutive business days as of January 28, 2026, and that, therefore, the Company is not in compliance with Nasdaq Listing… Filing
  22. Dec 10, 2025AgreementTuHURA Biosciences, Inc. entered into a securities purchase agreement with certain investors. Filing
  23. Dec 5, 2025AgreementAmendment to Secured Promissory Note and Loan Agreement As disclosed in a Current Report on Form 8-K filed by TuHURA Biosciences, Inc. on October 31, 2025, the Company previously entered into a Secured Promissory Note and Loan Agreement, dated October 27, 2025, with the Matthew Nachtrab Revocable… Filing
  24. Nov 25, 2025AnnouncementShared information with investors. Filing
  25. Nov 18, 2025AnnouncementUpdated Pro Forma Financial Statements As previously disclosed, on June 30, 2025, TuHURA Biosciences, Inc., a Nevada corporation, completed its previously announced acquisition contemplated by the Agreement and Plan of Merger, dated December 11, 2024, as amended by that certain First Amendment to… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

TuHURA Biosciences financials

Famous investors that hold HURA

2 of the 50 well-known investors we track reported holding HURA in their latest 13F filing. The largest position is Israel Englander's, worth $591K.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026281,328$591K0.0%-38%
Ken Griffin · Citadel AdvisorsQ3 202661,717$130K0.0%-73%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about TuHURA Biosciences, Inc./NV (HURA) stock

Who owns the most HURA stock?

The largest reported owner of TuHURA Biosciences, Inc./NV (HURA) is Vanguard Capital Management LLC, with 3.6% of the company. In total, 89 funds and institutions reported holding HURA at the end of Q2 2026, together about 14% of the shares. See the largest owners.

Are HURA insiders buying or selling?

No HURA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in HURA?

As of Oct 30, 2026, 6.20M HURA shares were sold short, 9.7% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 491,335 shares, buying them all back would take about 12.6 trading days (days to cover). See the history.

Have members of Congress traded HURA?

Yes. 1 member of Congress reported 2 purchases and 0 sales of HURA since Nov 17, 2024. The latest was reported on Aug 9, 2025. See the trades.

Which famous investors hold HURA?

2 of the 50 well-known investors we track reported HURA in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $591K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.